An add-on training program involving breathing exercises, cold exposure, and meditation attenuates inflammation and disease activity in axial spondyloarthritis – A proof of concept trial

Autoři: G. A. Buijze aff001;  H. M. Y. De Jong aff002;  M. Kox aff003;  M. G. van de Sande aff002;  D. Van Schaardenburg aff002;  R. M. Van Vugt aff005;  C. D. Popa aff006;  P. Pickkers aff003;  D. L. P. Baeten aff002
Působiště autorů: Department of Orthopaedic Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands aff001;  Department of Rheumatology and Clinical Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands aff002;  Department of Intensive Care Medicine, Nijmegen Institute for Infection, Inflammation and Immunity, RadboudUMC Nijmegen, Nijmegen, The Netherlands aff003;  Reade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands aff004;  Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands aff005;  Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands aff006;  Department of Rheumatology, RadboudUMC Nijmegen, Nijmegen, The Netherlands aff007
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article



The primary objective of this trial was to assess safety and anti-inflammatory effects of an add-on training program involving breathing exercises, cold exposure, and meditation in patients with axial spondyloarthritis


This study was an open-label, randomised, one-way crossover clinical proof-of-concept trial. Twenty-four patients with moderately active axial spondyloarthritis(ASDAS >2.1) and hs-CRP ≥5mg/L were included and randomised to an intervention (n = 13) and control group (n = 11) group that additionally received the intervention after the control period. The intervention period lasted for 8 weeks. The primary endpoint was safety, secondary endpoints were change in hs-CRP, serum calprotectin levels and ESR over the 8-week period. Exploratory endpoints included disease activity measured by ASDAS-CRP and BASDAI, quality of life (SF-36, EQ-5D, EQ-5D VAS), and hospital anxiety and depression (HADS).


We found no significant differences in adverse events between groups, with one serious adverse event occurring 8 weeks after end of the intervention and judged ‘unrelated’. During the 8-week intervention period, there was a significant decline of ESR from (median [interquartile range] to 16 [9–26.5] to 9 [5–23] mm/hr, p = 0.040, whereas no effect was found in the control group (from 14 [8.3–27.3] to 16 [5–37] m/hr, p = 0.406). ASDAS-CRP declined from 3.1 [2.5–3.6] to 2.3 [1.9–3.2] in the intervention group (p = 0.044). A similar trend was observed for serum calprotectin (p = 0.064 in the intervention group versus p = 0.182 in the control group), but not for hs-CRP.


This proof-of-concept study in axial spondyloarthritis met its primary endpoint with no safety signals during the intervention. There was a significant decrease in ESR levels and ASDAS-CRP upon the add-on training program in the intervention group. These findings warrant full-scale randomised controlled trials of this novel therapeutic approach in patients with inflammatory conditions.

Trial registration; NCT02744014

Klíčová slova:

Adverse events – Breathing – Exercise – Immune response – Inflammatory bowel disease – Inflammatory diseases – NSAIDs – Quality of life


1. Kox M, Stoffels M, Smeekens SP, van Alfen N, Gomes M, Eijsvogels TMH, et al. The influence of concentration/meditation on autonomic nervous system activity and the innate immune response: a case study. Psychosom Med. 2012;74(5):489–94. doi: 10.1097/PSY.0b013e3182583c6d 22685240

2. Kox M, van Eijk LT, Zwaag J, van den Wildenberg J, Sweep FCGJ, van der Hoeven JG, et al. Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. Proc Natl Acad Sci U S A. 2014;111(20):7379–84. doi: 10.1073/pnas.1322174111 24799686

3. Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–37. doi: 10.1016/S0140-6736(11)60071-8 21684383

4. Ambarus C, Yeremenko N, Tak PP, Baeten D. Pathogenesis of spondyloarthritis. Curr Opin Rheumatol. 2012;24(4):351–8. doi: 10.1097/BOR.0b013e3283534df4 22488076

5. van Tok MN, Satumtira N, Dorris M, Pots D, Slobodin G, van de Sande MG, et al. Innate immune activation can trigger experimental spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats. Front Immunol. 2017;8(AUG):1–12.

6. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83. doi: 10.1136/ard.2009.108233 19297344

7. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18–24. doi: 10.1136/ard.2008.094870 18625618

8. Turina MC, Yeremenko N, Paramarta JE, Rycke L De, Baeten D. Calprotectin (S100A8 / 9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. 2014;1–9.

9. Garrett S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91. 7699630

10. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36) I. Conceptual Framework and Item Selection. 2012;30(6):473–83.

11. Group E. EuroQol *—a new facility for the measurement of health-related quality of life. 1990;16:199–206. doi: 10.1016/0168-8510(90)90421-9 10109801

12. Zigmond A, Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x 6880820

Článek vyšel v časopise


2019 Číslo 12
Nejčtenější tento týden